Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy  by Wada, Takashi et al.
Kidney International, Vol. 58 (2000), pp. 1492–1499
Up-regulation of monocyte chemoattractant protein-1 in
tubulointerstitial lesions of human diabetic nephropathy
TAKASHI WADA, KENGO FURUICHI, NORIHIKO SAKAI, YASUNORI IWATA, KEIICHI YOSHIMOTO,
MIHO SHIMIZU, SHIN-ICHI TAKEDA, KAZUYA TAKASAWA, MITSUHIRO YOSHIMURA, HIROSHI KIDA,
KEN-ICHI KOBAYASHI, NAOFUMI MUKAIDA, TAKERO NAITO, KOUJI MATSUSHIMA,
and HITOSHI YOKOYAMA
First Department of Internal Medicine and Division of Blood Purification, School of Medicine, and Department of Molecular
Oncology, Cancer Research Institute, Kanazawa University, Kanazawa; Department of Internal Medicine, Kurobe Municipal
Hospital, Kurobe; Kanazawa National Hospital, Kanazawa; Toyama Prefectural Central Hospital, Toyama; and Department of
Molecular Preventive Medicine, School of Medicine, University of Tokyo, Tokyo, Japan
Up-regulation of monocyte chemoattractant protein-1 in tubu- feature of human diabetic nephropathy [1]. There may
lointerstitial lesions of human diabetic nephropathy. be an interplay of metabolic and hemodynamic pathways
Background. We previously described that monocyte che- in the progression of diabetic nephropathy [2–4]. Formoattractant protein-1 (MCP-1) plays an important role in
example, the renin-angiotensin system has been postu-progressive glomerular and interstitial damage in inflammatory
lated to have a pathogenic role in the development of dia-renal diseases. However, the expression of MCP-1 in diabetic
nephropathy remains to be investigated. betic nephropathy. Angiotensin II, especially, has many
Methods. We examined whether locally expressed MCP-1 nonhemodynamic effects on renal cells that may contrib-
participates in human diabetic nephropathy via recruiting and ute to the progression of diabetic nephropathy [5]. An-activating monocytes/macrophages (M f ). Urinary and serum
giotensin II induces hypertrophy and/or proliferation ofMCP-1 levels were measured by enzyme-linked immunosor-
glomerular and tubular epithelial cells, stimulates thebent assay in 45 patients with diabetic nephropathy. The pres-
ence of MCP-1 in diseased kidneys was determined by immuno- synthesis of collagen and fibronectin, and finally, reduces
histochemical and in situ hybridization analyses. extracellular matrix (ECM) turnover [5]. In addition to
Results. Urinary MCP-1 levels were significantly elevated metabolic and hemodynamic pathways, the infiltration ofin patients with diabetic nephrotic syndrome and advanced
inflammatory cells such as monocytes/macrophages (Mf )tubulointerstitial lesions. Moreover, urinary levels of MCP-1
into the diseased kidneys is a hallmark of the progressionwere well correlated with the number of CD68-positive infil-
trating cells in the interstitium. In contrast, serum MCP-1 levels of diabetic nephropathy [6]. Infiltrated M f release lyso-
remained similar to those of healthy volunteers. Furthermore, somal enzymes, nitrous oxide (NO), reactive oxygen in-
we detected the MCP-1–positive cells in the interstitium of
termediates (ROIs), and transforming growth factor-bdiabetic nephropathy via both immunohistochemical and in
(TGF-b), which have been reported to play an essentialsitu hybridization analyses.
Conclusion. These observations suggest that locally pro- role in renal damage [4, 7–9]. However, the mechanisms
duced MCP-1 may be involved in the development of advanced of the infiltration and activation of inflammatory M f in
diabetic nephropathy, especially in the formation of tubuloin- the diseased kidneys remain to be investigated in theterstitial lesions possibly through M f recruitment and activa-
pathogenesis of human diabetic nephropathy.tion. Moreover, up-regulation of MCP-1 may be a common
A chemokine, monocyte chemoattractant protein-1pathway involved in the progressive tubulointerstitial damage
in diabetic nephropathy as well as inflammatory renal diseases. [MCP-1; also termed as monocyte chemotactic and acti-
vating factor (MCAF)], was found to be secreted by
mononuclear cells and various nonleukocytic cells, in-
The accumulation of matrix proteins resulting in glo- cluding inflammatory fibroblasts, astrocytes, and renal
merular sclerosis and interstitial fibrosis is a prominent resident cells, including mesangial cells and tubular epi-
thelial cells [10, 11]. Recent studies reveal that MCP-1
plays an important role in the pathogenesis of crescenticKey words: chemokine, diabetes mellitus, kidney, interstitium, trans-
forming growth factor-b, macrophage/monocyte. formation and progressive tubulointerstitial lesions via
Mf recruitment and activation in experimental glomeru-Received for publication October 28, 1999
lonephritis models [12–14] and human nephritis [15–17].and in revised form April 6, 2000
Accepted for publication April 19, 2000 However, the role of MCP-1 in the pathogenesis of dia-
betic nephropathy remains unknown.Ó 2000 by the International Society of Nephrology
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To determine whether locally produced MCP-1 partic- trary scale from 0 to III: grade 0, not noted; grade I,
patchy; grade II, zonal; and grade III, diffuse. The sever-ipates in the pathophysiology of human diabetic ne-
ity of nephrosclerosis (arteriolosclerosis) according tophropathy by M f recruitment and activation, we deter-
hyalin deposits is as follows: grade 0, not noted; grademined the urinary levels of MCP-1 in patients with
I, noted, but less than half around the arteriole; grade II,diabetic nephropathy and investigated the relationship
noted more than half around the arteriole; and grade III,between MCP-1 levels and renal damage.
noted all around the arteriole. Nodular lesions, exudative
lesions, and mesangiolysis were simply shown as to
METHODS whether they were present in each specimen. The sever-
Patients ity of the diffuse lesions of glomeruli was graded on a
scale of 0 to IV according to the description by GellmanTwenty healthy subjects (10 males and 10 females;
et al [19].median age, 57.1 years; range, 16 to 82 years) and 45 pa-
tients (32 males and 13 females; median age, 61.1 years;
MCP-1 measurementsrange, 41 to 82 years) with type II (non-insulin-depen-
Spontaneously voided midstream urine catches weredent) diabetes mellitus were evaluated in this study. Pa-
collected on the morning of renal biopsy. Ten milliliterstients with underlying diseases such as other metabolic
of the each urine specimen were spun at 200 3 g fordiseases, liver diseases, pancreatitis, steroid-induced glu-
five minutes at room temperature to remove cells andcose intolerance, and primary or secondary renal dis-
precipitates. Serum samples were obtained from patientseases, except for diabetic nephropathy, were excluded
at the same time. The urinary supernatants and serafrom this study. Twenty-three patients had pathological
were kept frozen at 2708C until measurement. MCP-1diagnoses verified by renal biopsy. Patients were divided
levels were determined by an enzyme-linked immuno-into four groups in terms of proteinuria: negative, micro-
sorbent assay (ELISA), using a specific murine mono-albuminuria (albumin excretion rate between 20 and 200
clonal antihuman MCP-1 antibody (clone ME 69) as amg/min), proteinuria (macroalbuminuria, .200 mg/min,
capture and a rabbit polyclonal antibody as the secondup to 3.5 g/day), and massive urinary protein excretion
antibody as previously described [16]. The recovery rate(.3.5 g/day) showing nephrotic syndrome. Microalbumi-
was confirmed to be more than 95% up to 3 ng/mL innuria was determined using as immunoturbidimetric
these ELISA systems. All assays were performed in du-method [18]. Ten patients with minimal-change ne-
plicate. The detection limits of this ELISA system werephrotic syndrome (proteinuria for less than 1 month)
40 pg/mL for human MCP-1. Urinary MCP-1 levels were
and six patients with membranous nephropathy (protein- standardized by the amount of creatinine in the urine.
uria for more than 6 months) had nephrotic range pro-
teinuria ($3.5 g/day) as disease controls. In addition, Immunohistochemical studies
urine samples from six hypertensive patients with micro- The presence of MCP-1 protein was demonstrated im-
albuminuria were used for the measurement of MCP-1 munohistochemically on formalin-fixed, paraffin-embed-
as nondiabetic disease controls. The patients in this study ded tissue sections treated with catalyzed signal ampli-
were chosen consecutively from May 1988 to October fication system (Dako, Glostrup, Denmark) using the
1998 at Kanazawa University Hospital or its affiliate indirect avidin-biotinylated peroxidase complex method
hospitals. Urinary tract infections were ruled out in all with a specific murine monoclonal antihuman MCP-1
cases by means of bacterial cultures, the microscopic antibody (26j2). Normal mouse IgG1, which had been
findings, or both, because urinary tract infection is associ- absorbed with both human liver extracts and immuno-
ated with increased urinary MCP-1 levels (data not globulin, was used as a negative control. In addition, the
shown). All renal biopsies were performed with the con- absorption test was performed using a monoclonal anti-
sent of the patients. human MCP-1 antibody with excess recombinant MCP-1
as a negative control. MCP-1–positive cells were counted
Pathological studies from more than randomly chosen 10 fields under high-
Twenty-three kidney specimens were obtained by re- power magnification (3200). CD68-positive cells were
nal biopsy. Kidney specimens fixed in 10% buffered for- detected immunohistochemically on formalin-fixed, par-
malin (pH 7.2), embedded in paraffin, cut at 4 mm, and affin-embedded tissue sections treated by proteinase K
stained with hematoxylin and eosin, periodic acid-Schiff for five to six minutes at room temperature using murine
(PAS) reagent, periodic acid silver methenamine (PAM), antihuman macrophage CD68 monoclonal antibody (clone
and mallory-azan were observed under a light micro- KP1; Dako). CD68-positive M f were counted from all
scope. Each specimen contained 10 or more glomeruli. glomeruli and were expressed as the number of positive
We especially laid stress on those specimens stained with cells per glomerulus. Mean interstitial CD68-positive M f
PAM and PAS. The extent of interstitial fibrosis and were counted from more than randomly chosen 10 fields
under high-power magnification (3200).tubular atrophy was evaluated and graded on an arbi-
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Fig. 1. Urinary monocyte chemoattractant protein-1 (MCP-1) levels Fig. 2. Urinary levels of MCP-1 increased in patients with massive
in patients with diabetic nephropathy were significantly elevated. Values proteinuria. Values are mean 6 SEM. **P , 0.01.
are mean 6 SEM.
in diabetic nephropathy were not significantly higherIn situ hybridization for MCP-1
than those of healthy subjects (52.5 6 12.2 pg/mL vs.
In situ hybridization procedures were the same as those
74.0 6 0.5 pg/mL, respectively). Urinary levels of MCP-1previously described [16]. A partial sequence of mRNA
remained low in patients without protein excretion(59-CAGAGACTTTCATGCTGGAGGCGAGACTG
(1.8 6 0.2 pg/mg · creatinine, N 5 5). Patients withCGAGCTT-39) was used for the MCP-1 antisense oligo-
microalbuminuria (3.8 6 1.2 pg/mg · creatinine, N 5 6)nucleotide probe [20]. Signals were visualized by using
and patients with proteinuria (3.7 6 0.5 pg/mg · creati-commercially available digoxigenin-alkaline phospha-
nine, N 5 27) showed slightly elevated, but not signifi-tase system (DIG Oligonucleotide Tailing kit and Nu-
cantly higher levels of MCP-1 as compared with those ofcleic Acid Detection kit; Boehringer Mannheim Bio-
healthy subjects or diabetic patients without proteinuria.chemica, Mannheim, Germany). Negative controls were
Patients with massive proteinuria showing nephrotic syn-performed by replacing the antisense probe with a sense
drome showed significantly elevated urinary MCP-1 lev-probe for MCP-1, which was the exact complement of
els (23.2 6 9.2 pg/mg · creatinine, N 5 7) as comparedthe antisense probe (59-AAGCTCGCACTCTCGCCT
with those of healthy subjects and other diabetic patientsCCAGCATGAAAGTCTCTG-39).
(Fig. 2). Furthermore, among the patients with protein-
uria and massive proteinuria, urinary levels of MCP-1Statistics
significantly correlated with proteinuria (r 5 0.59, P 5Values are mean 6 SEM. Statistical significance was
0.0003, N 5 34). Diabetic patients with nephrotic syn-analyzed using Student’s t-test, analysis of variance
drome had significantly severe nephropathy of both glo-(ANOVA) test, Spearman’s and Pearson’s correlation
merular lesions (diffuse lesions, 3.5 6 0.2) and tubuloin-coefficient for the analyses of nonparametric and para-
terstitial lesions (interstitial fibrosis, 2.5 6 0.2; tubularmetric data. P , 0.05 was considered to be statistically
atrophy, 2.5 6 0.2; nephrosclerosis, 2.5 6 0.2) comparedsignificant.
with those of other diabetic patients (diffuse lesions,
1.7 6 0.2; interstitial fibrosis, 1.1 6 0.2; tubular atrophy,
RESULTS 1.2 6 0.3; nephrosclerosis, 1.6 6 0.3, P # 0.05, respec-
MCP-1 levels in diabetic nephropathy tively). In contrast, patients with minimal-change ne-
phrotic syndrome showing massive urinary protein excre-Elevated levels of urinary MCP-1 were detected in
tion as disease controls showed lower levels of MCP-1the urine sample in patients with diabetic nephropathy
in urine (1.6 6 0.4 pg/mg · creatinine). In addition, pa-(6.5 6 1.7 pg/mg · creatinine, mean 6 MEM) as com-
tients with membranous nephropathy also showed rela-pared with those of healthy subjects (1.0 6 0.1 pg/mg ·
creatinine; Fig. 1). In contrast, serum levels of MCP-1 tively low levels of urinary MCP-1 (3.9 6 1.0 pg/mg ·
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Fig. 3. Correlation of urinary MCP-1 levels
and tubulointerstitial lesions in diabetic ne-
phropathy. Urinary levels of MCP-1 increased
in accordance with the damage of interstitial
fibrosis (A) or tubular atrophy (B). In addi-
tion, there was a significant correlation be-
tween urinary MCP-1 levels and the severity
of nephrosclerosis (C). Values are mean 6
SEM. *P , 0.05; **P , 0.01 by analysis of
variance test.
creatinine), which did not give a significant difference Correlation of urinary MCP-1 levels and glomerular
from those of healthy subjects. As disease controls in lesions in diabetic nephropathy
nondiabetic populations, urinary levels of MCP-1 in hy- Urinary levels of MCP-1 increased in accordance with
pertensive patients with microalbuminuria remained as the damage of glomerular diffuse lesions, as was ob-
low as those of normal subjects (1.2 6 0.4 pg/mg · creati- served in the tubulointerstitial lesions (Fig. 4). MCP-1
nine, N 5 6). These results suggest that there might levels in urine were significantly elevated in patients with
be no correlation between levels of urinary MCP-1 and severe diffuse lesions (grade I, 2.9 6 0.9 pg/mg · creati-
massive proteinuria showing nephrotic syndrome caused nine, N 5 7; grade II, 2.6 6 1.0 pg/mg · creatinine, N 5
by noninflammatory glomerular capillary lesions. 6; grade III, 7.5 6 1.4 pg/mg · creatinine, N 5 6; grade
IV, 30.5 6 19.1 pg/mg · creatinine, N 5 4, P , 0.05 whenCorrelation of urinary MCP-1 levels and
compared with grades I to III; Fig. 4A). In addition, thetubulointerstitial lesions in diabetic nephropathy
patients with nodular lesions showed significantly higher
Urinary levels of MCP-1 increased in accordance with levels of urinary MCP-1 than those without them (4.1 6
the damage of tubulointerstitial lesions (Fig. 3). MCP-1
0.9 vs. 17.8 6 10.2 pg/mg · creatinine, P , 0.05, N 5 16
levels in urine were significantly elevated in patients with
and 7, respectively; Fig. 4B). Furthermore, there was asevere interstitial fibrosis (grade 0, 0.9 6 0.1 pg/mg ·
significant elevation of urinary levels of MCP-1 in pa-creatinine, N 5 2; grade I, 3.8 6 0.9 pg/mg · creatinine,
tients with exudative lesions as compared with thoseN 5 11; grade II, 6.2 6 1.6 pg/mg · creatinine, N 5 7;
without exudative lesions (4.6 6 0.9 vs. 22.1 6 15.5grade III, 29.0 6 19.9 pg/mg · creatinine, N 5 3, P , 0.05
pg/mg · creatinine, P , 0.01, N 5 18 and 5, respectively;when compared with grades 0 to II; Fig. 3A). Similarly,
Fig. 4C). Finally, there was a significant correlation be-urinary levels of MCP-1 increased in accordance with
tween urinary MCP-1 levels and the presence of mesangi-the severity of tubular atrophy (grade 0, 0.9 6 0.1 pg/mg ·
olysis (3.6 6 0.8 vs. 19.1 6 9.9 pg/mg · creatinine, P ,creatinine, N 5 2; grade I, 3.3 6 0.8 pg/mg · creatinine,
0.05, N 5 17 and 6, respectively; Fig. 4D). By comparison,N 5 9; grade II, 5.6 6 1.3 pg/mg · creatinine, N 5 9;
there was no significant correlation between the levelsgrade III, 30.6 6 19.0 pg/mg · creatinine, N 5 3, P ,
of urinary MCP-1 and the number of CD68-positive cells0.05 when compared with grade 0 to II; Fig. 3B). In
in the glomerulus in patients with diabetic nephropathyaddition, there was a significant correlation between uri-
(r 5 0.10, P 5 0.71, N 5 23).nary MCP-1 levels and the severity of nephrosclerosis
(grades 0 and I, 2.1 6 0.4 pg/mg · creatinine, N 5 7;
Detection of MCP-1 proteins and transcripts ingrades II and III, 10.1 6 4.0 pg/mg · creatinine, N 5 16,
renal tissuesP , 0.05; Fig. 3C). Furthermore, there was a significant
To determine the local production of MCP-1, renalcorrelation between the levels of urinary MCP-1 and
tissue from 23 patients with diabetic nephropathy wasthe number of CD68-positive cells in the interstitium in
examined via an immunohistochemical as well as in situpatients with diabetic nephropathy (r 5 0.63, P , 0.05,
N 5 23). hybridization technique for MCP-1. The representative
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Fig. 4. Correlation of urinary MCP-1 levels
and glomerular lesions in diabetic nephropa-
thy. Urinary levels of MCP-1 increased in ac-
cordance with the damage of glomerular dif-
fuse lesions (A). In addition, the patients with
nodular lesions (B), exudative lesions (C), and
the presence of mesangiolysis (D) showed sig-
nificantly higher levels of urinary MCP-1. Val-
ues are mean 6 SEM. *P , 0.05; **P , 0.01
by analysis of variance test.
Fig. 5. Detection of MCP-1 in diabetic nephropathy. Expression of MCP-1 protein in renal tissues was detected using a specific monoclonal anti-
human MCP-1 antibody as described in the Methods section. The sections were observed under a light microscope. The representative case who
had advanced diabetic nephropathy [diffuse lesion III, nodular lesion (1), exudative lesion (2), mesangiolysis (2), interstitial fibrosis III, tubular
atrophy III, nephrosclerosis II] with nephrotic syndrome (4.2 g/day) was shown here. MCP-1–positive cells were observed mainly in the endothelial,
tubular epithelial cells (arrowheads), and infiltrated cells in the interstitium (a, 3200). In situ hybridization detected MCP-1 mRNA mainly in
cortical tubuli, peritubular capillary endothelial cells, and infiltrated mononuclear cells (arrows) in the interstitium, but it was not detected in the
glomeruli (b and c, 3200; n indicates nodular lesion).
case of a 42-year-old male who had advanced diabetic N 5 23) was correlated with urinary levels of MCP-1
nephropathy [diffuse lesion III, nodular lesion (1), exu- (r 5 0.52, P , 0.05, N 5 23). Furthermore, in situ hybrid-
dative lesion (2), mesangiolysis (2), interstitial fibrosis ization detected MCP-1 mRNA signals mainly in cortical
III, tubular atrophy III, nephrosclerosis II] with ne- tubuli, peritubular capillary endothelial cells, and infil-
phrotic syndrome (4.2 g/day) was shown in Figure 5. trated mononuclear cells in the interstitium, but it was
MCP-1–positive cells were detected in cortical tubuli, not detected in the glomeruli (Fig. 5 b, c). These stainings
peritubular capillary endothelial cells, and infiltrated were specific because positive staining was not detected
mononuclear cells in the interstitium in patients with when the tissues were hybridized with sense oligonucleo-
diabetic nephropathy, but was not detected in diseased tide probe for MCP-1 (data not shown).
glomeruli (Fig. 5a). The staining was specific to MCP-1
because neither control isotype-matched murine IgG nor
DISCUSSIONantibody absorbed with recombinant MCP-1 stained
The present study demonstrated that up-regulation ofpositively (data not shown). In addition, the number of
MCP-1–positive cells in interstitium (12.3 6 0.8 per field, locally produced MCP-1 may be involved in advanced
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tubulointerstitial lesions in diabetic patients with ne- eased glomeruli, nor the correlation between the number
of CD68-positive cells in glomeruli with urinary levelsphrotic syndrome possibly through M f recruitment and
of MCP-1. Similarly, we previously reported that urinaryactivation. This concept is based on our findings that
levels of MCP-1 were well correlated with mesangial(1) urinary MCP-1 levels were significantly elevated in
proliferation of IgA nephropathy, even though MCP-1patients with diabetic nephrotic syndrome and advanced
was not detected in the diseased glomeruli by an immu-tubulointerstitial lesions. (2) Urinary levels of MCP-1
nohistochemical study [17]. These results may be derivedwere correlated with CD68-positive M f in interstitium.
from the close association between glomerular and tubu-(3) We detected MCP-1–positive cells in advanced tubu-
lointerstitial lesions in each patient of diabetic nephropa-lointerstitial lesions of diabetic nephropathy. (4) Urinary
thy. Supporting this notion, we previously reported thatMCP-1 excretion was correlated with the number of
there are three phases in the process of the progressionMCP-1–positive cells in the interstitium of renal biopsy
of diabetic glomerulosclerosis: In the first phase, arterio-specimens. (5) Patients with minimal-change nephrotic
sclerosis and diffuse lesions appear. In the second phase,syndrome or membranous nephropathy showed lower
mesangiolysis and nodular lesions develop in associationlevels of urinary MCP-1, suggesting that massive protein-
with moderately advanced arteriolosclerosis, and in theuria showing nephrotic syndrome did not directly induce
third phase, exudative lesions and hyalinized glomeruli
elevated levels of urinary MCP-1. appear in association with advanced arteriosclerosis
In this study, the expression of MCP-1 was observed (nephrosclerosis) together with advanced interstitial le-
to be up-regulated in the interstitium by immunohisto- sions [25, 26]. Moreover, in the development of mesangi-
chemical and in situ hybridization analyses: tubular epi- olysis and layered nodular lesions, disturbed blood flow
thelial, endothelial cells, and mononuclear infiltrates. In into glomeruli in the consequence of diabetic arteriolo-
addition, urinary MCP-1 levels were significantly ele- sclerosis (nephrosclerosis) could be essential [25, 26].
vated in patients with diabetic nephrotic syndrome and Even though there was no direct evidence of MCP-1
advanced tubulointerstitial lesions. Patients with mini- expression in glomerular lesions, MCP-1 may have an
mal-change nephrotic syndrome or membranous ne- indirect impact on glomerular lesions via the progression
phropathy showed lower levels of urinary MCP-1. These of arteriolosclerosis (nephrosclerosis). Hence, the role
data suggest that elevated levels of urinary MCP-1 may of MCP-1 in the pathogenesis of diabetic glomerular
reflect advanced tubulointerstitial lesions in diabetic pa- lesions requires further investigation.
tients. Supporting this notion, we previously reported It is likely that the pathophysiology of diabetic ne-
that MCP-1 plays a pivotal role in the progressive tubulo- phropathy involves an interaction of metabolic and he-
modynamic factors [4]. Relevant metabolic factors in-interstitial damage and promotes renal dysfunction in
clude glucose-dependent pathways such as advancedcrescentic glomerulonephritis [15], human lupus nephri-
glycation, increased formation of polyols, oxidant stress,tis [16], IgA nephropathy [17], and an experimental glo-
and activation of the enzyme protein kinase C [4, 27].merulonephritis model [12]. Progressive renal diseases
Supporting this notion, oxidatively modified lipoproteinshave been reported to be associated with tubulointersti-
found in diabetic plasma stimulate MCP-1 gene expres-tial involvement, and there may be a strict correlation
sion in endothelial cells [28]. In addition, hemodynamicbetween tubular atrophy, interstitial fibrosis, the extent
factors include the role of vasoactive hormones, such asof interstitial infiltrates, and the renal dysfunction [21].
angiotensin II. Angiotensin II-dependent pathways toIn addition, interstitial involvement is thought to be the
MCP-1 up-regulation have been shown to play an impor-common pathological finding resulting in end-stage renal
tant role in glomerular and tubulointerstitial damagediseases in spite of causes of renal damages. Thus far,
[29–31]. Therefore, these factors, observed in the pro-TGF-b has been thought to be the candidate for the key
gression of diabetes mellitus, may stimulate the expres-factor to the progression of glomerular and tubuloin-
sion of MCP-1 in the diseased kidneys. Alternatively,terstitial lesions, including both nephritis and diabetic
massive proteinuria might induce tubular epithelial cells
nephropathy [22]. A recent study revealed that MCP-1 to activate lysosome and antigen presentation followed
mediates collagen deposition in experimental glomerulo- by the activation of helper T cells in the interstitium
nephritis by TGF-b [23]. In addition, TGF-b may con- [32, 33]. However, at least concerning MCP-1, protein-
tribute to the secretion of tubular MCP-1 in nephrotic uria itself did not induce the up-regulation of MCP-1,
syndrome [24]. Therefore, MCP-1 associated with the because patients with minimal-change nephrotic syn-
up-regulation of TGF-b may be a common pathway drome and membranous nephropathy showing massive
involved in the advanced tubulointerstitial damage in proteinuria had lower levels of urinary MCP-1. Taken
diabetic nephropathy as well as in inflammatory renal together, once endothelial cells, tubular epithelial cells,
diseases. and interstitial infiltrates have been activated by some
Urinary levels of MCP-1 were elevated in accordance metabolic and/or hemodynamic process, these cells pro-
with the progression of diabetic glomerular lesions. How- duce MCP-1, and in turn, MCP-1 may be involved in
the progression of advanced tubulointerstitial lesions.ever, there was neither the detection of MCP-1 in dis-
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